Patient, disease, and transplant characteristics by donor source
| . | Umbilical cord blood, N = 186, N (%)* . | Haploidentical relative, N = 182, N (%)* . |
|---|---|---|
| Sex | ||
| Female | 89 (48) | 76 (42) |
| Male | 97 (52) | 106 (58) |
| Age, median (range), y | 58 (20-70) | 60 (20-70) |
| Ethnic origin | ||
| White | 145 (78) | 126 (69) |
| African American | 27 (15) | 34 (19) |
| Other | 14 (7) | 22 (12) |
| Hispanic or Latino | ||
| Yes | 22 (12) | 21 (12) |
| No | 164 (88) | 159 (87) |
| Unknown or not answered | 0 | 2 (1) |
| Performance score | ||
| 90-100 | 126 (68) | 111 (61) |
| 80-70 | 60 (32) | 71 (39) |
| Hematopoietic comorbidity index | ||
| ≤2 | 104 (59) | 99 (59) |
| ≥3 | 71 (41) | 68 (41) |
| Cytomegalovirus serostatus | ||
| Positive | 98 (56) | 99 (59) |
| Negative | 76 (43) | 68 (41) |
| Not reported | 1 (<1) | |
| Disease | ||
| Acute lymphoblastic leukemia | 31 (17) | 32 (18) |
| Acute myeloid leukemia | 98 (53) | 98 (54) |
| Biphenotypic leukemia | 1 (<1) | 5 (3) |
| T-cell leukemia/lymphoma | 4 (2) | 3 (2) |
| Hodgkin lymphoma | 10 (6) | 8 (4) |
| Large cell lymphoma | 21 (11) | 19 (10) |
| Follicular non-Hodgkin lymphoma | 7 (4) | 5 (3) |
| Mantle cell lymphoma | 6 (3) | 5 (3) |
| Other lymphoma | 8 (4) | 7 (4) |
| Disease status at transplant | ||
| Acute leukemia | ||
| First complete remission | 99 (74) | 117 (85) |
| Second complete remission | 35 (26) | 20 (15) |
| Third complete remission | 1 (<1) | |
| Lymphoma | ||
| Complete remission | 20 (39) | 14 (32) |
| Partial remission | 25 (48) | 25 (57) |
| Follicular lymphoma | 7 (14) | 5 (11) |
| Cytogenetic risk (leukemia only) | ||
| Favorable | 17 (13) | 20 (15) |
| Intermediate | 61 (46) | 56 (41) |
| Poor | 43 (32) | 45 (33) |
| Not reported | 13 (10) | 17 (12) |
| Disease risk index | ||
| Low | 23 (12) | 14 (8) |
| Intermediate | 119 (64) | 120 (66) |
| High | 35 (19) | 37 (20) |
| Not evaluable | 9 (5) | 11 (6) |
| Infused nucleated cell dose, ×107/kg | ||
| Median (IQR) | 2.95 (1.85-4.32) | 26.82 (18.76-36.35) |
| Infused CD34+dose, ×106/kg | ||
| Median (IQR) | 0.13 (0.07-0.23) | 2.87 (1.44-3.86) |
| Infused CD3+dose, ×106/kg | ||
| Median (IQR) | 5.50 (1.90-8.20) | 29.66 (22.48-42.87) |
| . | Umbilical cord blood, N = 186, N (%)* . | Haploidentical relative, N = 182, N (%)* . |
|---|---|---|
| Sex | ||
| Female | 89 (48) | 76 (42) |
| Male | 97 (52) | 106 (58) |
| Age, median (range), y | 58 (20-70) | 60 (20-70) |
| Ethnic origin | ||
| White | 145 (78) | 126 (69) |
| African American | 27 (15) | 34 (19) |
| Other | 14 (7) | 22 (12) |
| Hispanic or Latino | ||
| Yes | 22 (12) | 21 (12) |
| No | 164 (88) | 159 (87) |
| Unknown or not answered | 0 | 2 (1) |
| Performance score | ||
| 90-100 | 126 (68) | 111 (61) |
| 80-70 | 60 (32) | 71 (39) |
| Hematopoietic comorbidity index | ||
| ≤2 | 104 (59) | 99 (59) |
| ≥3 | 71 (41) | 68 (41) |
| Cytomegalovirus serostatus | ||
| Positive | 98 (56) | 99 (59) |
| Negative | 76 (43) | 68 (41) |
| Not reported | 1 (<1) | |
| Disease | ||
| Acute lymphoblastic leukemia | 31 (17) | 32 (18) |
| Acute myeloid leukemia | 98 (53) | 98 (54) |
| Biphenotypic leukemia | 1 (<1) | 5 (3) |
| T-cell leukemia/lymphoma | 4 (2) | 3 (2) |
| Hodgkin lymphoma | 10 (6) | 8 (4) |
| Large cell lymphoma | 21 (11) | 19 (10) |
| Follicular non-Hodgkin lymphoma | 7 (4) | 5 (3) |
| Mantle cell lymphoma | 6 (3) | 5 (3) |
| Other lymphoma | 8 (4) | 7 (4) |
| Disease status at transplant | ||
| Acute leukemia | ||
| First complete remission | 99 (74) | 117 (85) |
| Second complete remission | 35 (26) | 20 (15) |
| Third complete remission | 1 (<1) | |
| Lymphoma | ||
| Complete remission | 20 (39) | 14 (32) |
| Partial remission | 25 (48) | 25 (57) |
| Follicular lymphoma | 7 (14) | 5 (11) |
| Cytogenetic risk (leukemia only) | ||
| Favorable | 17 (13) | 20 (15) |
| Intermediate | 61 (46) | 56 (41) |
| Poor | 43 (32) | 45 (33) |
| Not reported | 13 (10) | 17 (12) |
| Disease risk index | ||
| Low | 23 (12) | 14 (8) |
| Intermediate | 119 (64) | 120 (66) |
| High | 35 (19) | 37 (20) |
| Not evaluable | 9 (5) | 11 (6) |
| Infused nucleated cell dose, ×107/kg | ||
| Median (IQR) | 2.95 (1.85-4.32) | 26.82 (18.76-36.35) |
| Infused CD34+dose, ×106/kg | ||
| Median (IQR) | 0.13 (0.07-0.23) | 2.87 (1.44-3.86) |
| Infused CD3+dose, ×106/kg | ||
| Median (IQR) | 5.50 (1.90-8.20) | 29.66 (22.48-42.87) |
N (%) unless otherwise stated in the row headings.